Brian G Fox

US Patent:

20090259503, Oct 15, 2009

Filed:

Jul 25, 2008

Appl. No.:

12/180299

Inventors:

W. Mark Allen - Millburn NJ, US
Michael T. Deimling - Chicago IL, US
Nicole Ann McCabe - Chicago IL, US
Steven H. Egert - Montgomery IL, US
Brian P. Fox - Christiana PA, US
Deanne M. George - Freeburg IL, US

Assignee:

ACCENTURE GLOBAL SERVICES GMBH - Schaffhausen

International Classification:

G06F 17/00

US Classification:

705 7

Abstract:

A system, method and tool are described for providing a business-driven learning solution. A learning plan is created where the learning plan is implemented in a course for a determined time period. The learning plan is displayed to a plurality of users. The learning plan is approved by the plurality of users. Thereafter, the learning plan is updated during the determined time period in accordance with changes to budget, prioritization and training needs. The updated learning plan is displayed to the plurality of users.

US Patent:

20140026121, Jan 23, 2014

Filed:

Jul 20, 2012

Appl. No.:

13/554335

Inventors:

Wayne Jackson - Columbia MD, US
Brian Edward Fox - Goffstown NH, US
Mike Hansen - Potomac Falls VA, US
Stuart McCulloch - Kenilworth, GB
Jason Van Zyl - Guelph, CA

Assignee:

SONATYPE, INC. - Silver Spring MD

International Classification:

G06F 9/44

US Classification:

717124

Abstract:

A computer system, method, or computer-readable medium corrects a broken portion of an application. A fingerprint indicates classes that comprise the application. The classes indicated in the fingerprint are looked up to determine whether any is broken. For a broken class, a fixed class is substituted when the broken class is loaded at class load time for the application; a fixed class method is substituted into the broken class, when the broken class is loaded at class load time; fixed byte code is substituted for broken byte code corresponding to the broken class, when the broken class is loaded at class load time; the broken class is unloaded and the fixed class is loaded instead, when the application is running; or the broken class is replaced inside the static application with the fixed class; all without replacing classes which are not broken.

US Patent:

20220298222, Sep 22, 2022

Filed:

Aug 21, 2020

Appl. No.:

17/636181

Inventors:

- Seattle WA, US
Ellen FILVAROFF - Summit NJ, US
Brian FOX - Seattle WA, US
Adithi MOHAN - Summit NJ, US
Katie NEWHALL - Seattle WA, US
Nels Eric OLSON - Seattle WA, US

Assignee:

Juno Therapeutics, Inc. - Seattle WA

International Classification:

C07K 14/725
A61P 35/00

Abstract:

Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of an enhancer of zeste homolog 2 (EZH2), for treating subjects having or suspected of having a cancer, and related methods, uses, and articles of manufacture. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs).

US Patent:

20220273654, Sep 1, 2022

Filed:

Jun 12, 2020

Appl. No.:

17/618415

Inventors:

- Summit NJ, US
Brian Fox - Summit NJ, US
Ida Aronchik - Summit NJ, US
Tracy Chow - Summit NJ, US

Assignee:

Celgene Corporation - Summit NJ

International Classification:

A61K 31/506
C07K 16/28
A61K 31/365
A61K 31/555

Abstract:

Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro- benzonitrile (compound of Formula (I)) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1) to patients in need thereof. Methods are further drawn to administering compositions described herein to patients having neoplastic cells that express RCOR2.

US Patent:

20230089536, Mar 23, 2023

Filed:

Mar 5, 2021

Appl. No.:

17/909292

Inventors:

- Summit NJ, US
Ida Aronchik - Sumit NJ, US
Tracy Chow - Sumit NJ, US
Eric Olson - Summit NJ, US
Brian Fox - Summit NJ, US
Maria Wang - Summit NJ, US

Assignee:

Celgene Quanticel Research, Inc. - Summit NJ

International Classification:

A61K 31/496
A61K 9/48
A61K 9/20
A61K 9/00
A61P 35/00

Abstract:

The present application relates generally to a lysine specific demethylase-1 (LSD-1) inhibitor, or a pharmaceutically acceptable salt thereof, and nivolumab, for use in methods for treating small cell lung cancer (SCLC) and/or squamous non-small cell lung cancer (sqNSCLC).

US Patent:

20170147338, May 25, 2017

Filed:

Nov 25, 2015

Appl. No.:

14/951923

Inventors:

- Fulton MD, US
Michael HANSEN - Potomac Falls VA, US
Brian FOX - Goffstown NH, US
Jaime WHITEHOUSE - Guelph, CA
Jason DILLON - San Jose CA, US

International Classification:

G06F 9/44

Abstract:

A computer system, method, or computer-readable medium controls a potentially unacceptable software component intended for a software repository. A pre-defined application or repository policy associated with the repository or application pre-defines risks and, for each of the risks, an action to take for the risk. The action can be a pass action or a does-not-pass action, which are pre-defined programmatic steps also defined in the policy. When the component is not new to the repository or the application, the component is passed through for the usual handling. When the component is new, risks are determined that match the software component; for risks which match, the actions are taken as defined in the pre-defined policy. The pass action can include adding the software component to the software repository. The does-not-pass action is followed for a component that does not pass as a potentially unacceptable software component.